YARDLEY, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ: OPTN ), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting discounts. The offering consists of 2,500,000 shares being sold by Optinose and 2,500,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately $52.3 million to Optinose and approximately $52.3 million to the selling stockholders, after deducting underwriting discounts and before offering expenses. In addition, Optinose and the selling stockholders have granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 750,000 shares at the public offering price, less the underwriting discount. Optinose will not receive any proceeds from the sale of shares by the selling stockholders.
The offering is expected to close on or about June 11, 2018, subject to satisfaction of customary closing conditions. Registration statements relating to these securities were declared effective by the Securities and Exchange Commission on June 6, 2018.
Jefferies and Piper Jaffray are acting as the lead book-running managers for the offering. BMO Capital Markets and RBC Capital Markets are also acting as joint book-running managers for the offering and Cantor is acting as sole lead manager. This offering is being made only by means of a prospectus. A copy of the final prospectus may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com ; Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at prospectus@pjc.com ; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, or by telephone at 800-414-3627 or by email at bmoprospectus@bmo.com ; and RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8 th Floor, New York, NY 10281-8098 or by telephone at 877-822-4089 or by email at equityprospectus@rbccm.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About Optinose Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway.
Optinose Investor Contact Jonathan Neely jonathan.neely@optinose.com 267.521.0531
